Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling.
Cancer Lett. 2019 Oct 28;463:11-26. doi: 10.1016/j.canlet.2019.08.003. Epub 2019 Aug 9.
Cancer Lett. 2019.
PMID: 31404613